Statin use and risk of remote seizure after first new onset status epilepticus

Abstract Objective Preclinical evidence supports the role of statins as antiepileptogenic agents. In this study, we investigated the risk of remote unprovoked seizures (RS) according to the use of statin therapy in a cohort of first‐ever status epilepticus (SE) survivors. Methods Retrospective analysis was made of adult patients (age ≥ 14 years) with a first SE who were consecutively and prospectively admitted to the Modena Academic Hospital, Italy (September 2015–December 2023) and included in the Modena Status Epilepticus Registry. Kaplan–Meier survival analyses were used to calculate the probability of RS following the index SE event, whereas Cox proportional hazard and competing risk regression models were used to assess predictors of RS occurrence. Results A total of 314 patients were included (mean age = 70 years, 63% females). The statin‐exposed cohort included both patients already receiving statins before SE ( n = 68) and patients in whom statin administration was started during the hospitalization ( n = 18). Atorvastatin (69/86, 80%) was the most frequently prescribed statin. Overall, 67 patients (21.3%) developed RS (mean follow‐up = 31.5 months). Cumulative probability of RS occurrence was 16%, 23%, and 32% at 12 months, 2 years, and 5 years after SE, respectively. Median time from index event to first RS was 6.9 months (interquartile range = 11.6 months). Cumulative probability of RS was significantly lower in statin users compared to nonusers (log‐rank p = .038). After adjusting for confounders, the risk of RS was lower for those patients who used statins after the index event (hazard ratio = .48, 95% confidence interval [CI] = .26–.90, p = .023). Significance The overall risk of RS was moderate and temporally confined within a few years from the index event. Statin exposure was associated with a lower incidence of RS. Our findings expand knowledge regarding a possible antiepileptogenic role of statins after SE and support further studies in this field.

Authors

Institutions

Publication Details

Journal
Epilepsia
Published
2026-09-15
DOI
https://doi.org/10.1002/epi.70503
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Statin use and risk of remote seizure after first new onset status epilepticus

Stefano Meletti, Matteo Pugnaghi, Simona Lattanzi, Simona Scolastico et al.
Epilepsia
Epilepsy research and treatment
article

Statin use and risk of remote seizure after first new onset status epilepticus

Stefano Meletti, Matteo Pugnaghi, Simona Lattanzi, Simona Scolastico, Giada Giovannini, Anna Elisabetta Vaudano, Lisa Taruffi, Niccolò Orlandi, Laura Madrassi, Margherita Burani, Leonardo Affronte, Mara Malerba, Jefe Laureine Ngnintedem Dontsop
article en

Abstract

Abstract Objective Preclinical evidence supports the role of statins as antiepileptogenic agents. In this study, we investigated the risk of remote unprovoked seizures (RS) according to the use of statin therapy in a cohort of first‐ever status epilepticus (SE) survivors. Methods Retrospective analysis was made of adult patients (age ≥ 14 years) with a first SE who were consecutively and prospectively admitted to the Modena Academic Hospital, Italy (September 2015–December 2023) and included in the Modena Status Epilepticus Registry. Kaplan–Meier survival analyses were used to calculate the probability of RS following the index SE event, whereas Cox proportional hazard and competing risk regression models were used to assess predictors of RS occurrence. Results A total of 314 patients were included (mean age = 70 years, 63% females). The statin‐exposed cohort included both patients already receiving statins before SE ( n = 68) and patients in whom statin administration was started during the hospitalization ( n = 18). Atorvastatin (69/86, 80%) was the most frequently prescribed statin. Overall, 67 patients (21.3%) developed RS (mean follow‐up = 31.5 months). Cumulative probability of RS occurrence was 16%, 23%, and 32% at 12 months, 2 years, and 5 years after SE, respectively. Median time from index event to first RS was 6.9 months (interquartile range = 11.6 months). Cumulative probability of RS was significantly lower in statin users compared to nonusers (log‐rank p = .038). After adjusting for confounders, the risk of RS was lower for those patients who used statins after the index event (hazard ratio = .48, 95% confidence interval [CI] = .26–.90, p = .023). Significance The overall risk of RS was moderate and temporally confined within a few years from the index event. Statin exposure was associated with a lower incidence of RS. Our findings expand knowledge regarding a possible antiepileptogenic role of statins after SE and support further studies in this field.

Epilepsia
University of Modena and Reggio Emilia (IT), Marche Polytechnic University (IT), University of Parma (IT), Azienda Ospedaliero-Universitaria di Modena (IT), Azienda Ospedaliera Universitaria Senese (IT)
Good health and well-being
Openalex Percentile: Top 10%
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.